-
10:28:01 PM
Sign in with email
Forgot your password?
Register with email
Account Verification

ENTA Stock News

10/19/21 7:00 AM
Nasdaq : ENTA
covid-19
Enanta Pharmaceuticals Presents New Data for EDP-235, its Lead Oral Protease Inhibitor Designed for the Treatment of COVID-19, at the ISIRV–WHO Virtual Conference 2021
Enanta Pharmaceuticals, Inc., a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported new preclinical data for EDP-235, its recently announced lead oral protease inhibitor specifically designed for the treatment of COVID-19. These data were presented in a poster titled“...
RHEA-AI
neutral
10/06/21 8:16 AM
Nasdaq : ENTA
clinical trialcovid-19
New Preclinical Data for EDP-235, Enanta’s Oral Protease Inhibitor Specifically Designed for the Treatment of COVID-19, to be Presented at ISRIV-WHO Virtual 2021 Conference: COVID-19, Influenza and RSV: Surveillance-Informed Prevention and Treatment
Enanta Pharmaceuticals, Inc., a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that new preclinical data for EDP-235, its lead oral protease inhibitor specifically designed for the treatment of COVID-19, will be presented at the International Society for...
RHEA-AI
neutral
10/05/21 7:00 AM
Nasdaq : ENTA
conferences
Enanta Pharmaceuticals to Present at the H.C. Wainwright 2nd Annual Hepatitis B Virus Virtual Conference
Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat on Wednesday, October 13, 2021, at 3:30 p.m. ET at the H.C. Wainwright 2 nd Annual Hepatitis B...
RHEA-AI
neutral
08/05/21 4:01 PM
Nasdaq : ENTA
earnings
Enanta Pharmaceuticals Reports Financial Results for Its Fiscal Third Quarter Ended June 30, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal third quarter ended June 30, 2021.“This was an important quarter for Enanta, and I
RHEA-AI
neutral
08/05/21 7:00 AM
Nasdaq : ENTA
covid-19
Enanta Pharmaceuticals Announces Nomination of Clinical Candidate EDP-235, its Lead Oral Protease Inhibitor Specifically Designed for the Treatment of COVID-19
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the nomination of EDP-235, its lead oral protease inhibitor specifically designed for the treatment of COVID-19.
RHEA-AI
neutral